简体中文 | 繁體中文 | English

Health and Pharmaceutical Press Releases

2024-02-22 15:24 Parse Biosciences Launches Evercode Whole Transcriptome Version 3, Boosting Usability and Performance
2024-02-22 10:11 TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada
2024-02-22 09:45 MMI Raises $110 Million in Series C Financing
2024-02-21 16:24 Sinovac Amends Shareholder Rights Plan
2024-02-21 13:27 AI Medical Service Inc. Completes First Regulatory Review and Device Registration of Gastric AI-based Endoscopic Diagnosis Support System from Singapore’s HSA
2024-02-21 13:24 MRM Health Initiates Clinical Research in Parkinson’s Disease
2024-02-21 11:27 Patient Safety Movement Foundation Outlines 2024 Action Plan for Creating a Safer Healthcare System
2024-02-21 10:00 Biocytogen and Gilead Enter Into a Multi-Target Antibody Collaboration Agreement
2024-02-18 15:51 CORRECTING and REPLACING, Galderma Announces Regulatory Filing Acceptance for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in the U.S. and EU
2024-02-18 09:58 Perfect Moment Announces Closing of Initial Public Offering
2024-02-09 11:47 Takeda Intends to Rapidly Initiate the First Global Phase 3 Trials of TAK-861, an Oral Orexin Agonist, in Narcolepsy Type 1 in First Half of Fiscal Year 2024
2024-02-08 17:08 Perfect Moment Announces Pricing of Initial Public Offering
2024-02-08 14:21 Galderma Takes the ‘Face of Cetaphil®’ to the Runway at New York Fashion Week
2024-02-08 10:34 Myrobalan Therapeutics Receives a Grant from the ALS Association to Advance its CSF1R Inhibitor Program
2024-02-07 14:16 Galderma Launches ‘NEXT’, a Ground-Breaking Trend Report That Unveils the Future of Aesthetics
2024-02-07 10:54 Parse Biosciences Partners with INTEGRA Biosciences for Automated Single Cell Workflows
2024-02-05 16:46 TauRx to Present Two-Year Data from Phase III Trial of HMTM in Alzheimer’s Disease at the AD/PD™ 2024 Conference in March
2024-02-04 13:20 Sirius Therapeutics Begins Phase 1 Clinical Trial of Next-Generation, Long-Acting Factor XI siRNA Anticoagulant for Treatment of Thromboembolic Disorders
2024-02-04 13:13 Clinique Partners with Icahn School of Medicine at Mount Sinai to Establish the Mount Sinai-Clinique Healthy Skin Dermatology Center
2024-02-04 13:06 Located in Seoul, Korea, Topcon Korea Medical Co., Ltd. (TKM) Was Established and Formally Launched in 2023.

Business Wire Weibo

Press Releases

Latest Releases